A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
- Conditions
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 14
- Registration Number
- NCT04882072
- Locations
- ๐ฏ๐ต
Niigata University Medical And Dental Hospital, Niigata, Japan
๐ฏ๐ตCenter Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
๐ฏ๐ตTokyo Medical and Dental University Hospital, Bunkyo Ku, Japan
An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa
- Conditions
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 15
- Registration Number
- NCT04868916
- Locations
- ๐ฏ๐ต
National Hospital Organization Tokyo Medical Center, Tokyo, Japan
A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 30
- Registration Number
- NCT04791332
- Locations
- ๐ฏ๐ต
Sumida Hospital, Tokyo, Japan
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 15
- Registration Number
- NCT04773522
- Locations
- ๐ฏ๐ต
Shonan Kamakura General Hospital, Kamakura-shi, Japan
๐ฏ๐ตNagoya City University Hospital, Nagoya, Japan
๐ฏ๐ตNational Hospital Organization Okayama Medical Center, Okayama, Japan
A Study of JNJ-61393215 in Healthy Japanese Male Participants
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 24
- Registration Number
- NCT04713930
- Locations
- ๐ฏ๐ต
Souseikai Hakata Clinic, Fukuoka, Japan
A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 40
- Registration Number
- NCT04696809
- Locations
- ๐ฏ๐ต
National Hospital Organization Hiroshima-Nishi Medical Center, Otake, Japan
๐ฏ๐ตKameda Medical Center, Chiba, Japan
๐ฏ๐ตOgaki Municipal Hospital, Gifu, Japan
A Study of Guselkumab in Participants With Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 56
- Registration Number
- NCT04683029
- Locations
- ๐ฏ๐ต
Chukyo Hospital, Aichi, Japan
๐ฏ๐ตWakayama Medical University Hospital, Wakayama, Japan
๐ฏ๐ตUniversity of Fukui Hospital, Yoshida, Japan
A Study of JNJ-40411813 in Healthy Japanese Male Participants
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 39
- Registration Number
- NCT04677530
- Locations
- ๐ฏ๐ต
Souseikai Fukuoka Mirai Hospital, Fukuoka-shi, Japan
A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 129
- Registration Number
- NCT04630145
- Locations
- ๐ฐ๐ท
Chonnam National University Hospital, Gwangju, Korea, Republic of
๐ฏ๐ตSt. Luke's International Hospital, Chuo ku, Japan
๐ฏ๐ตFukui Prefectural Hospital, Fukui-shi, Japan
A Study of Ad26.COV2.S in Adults (COVID-19)
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 250
- Registration Number
- NCT04509947
- Locations
- ๐ฏ๐ต
Souseikai Fukuoka Mirai Hospital, Fukuoka-shi, Japan
๐ฏ๐ตSouseikai Hakata Clinic, Fukuoka, Japan
๐ฏ๐ตSOUSEIKAI PS Clinic, Fukuoka, Japan